Trial intelligence / Profile preview

Phase 3 LY900014 Added to Insulin in Type 1 Diabetes

jRCT2080223613Phase 3Completed

Sponsor
Eli Lilly and Company
Start
Aug 2017
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of insulin lispro in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Eli Lilly and Company. Started Aug 2017; status: completed.

02

Drugs

insulin lispro
03

Conditions

diabetes mellitus type 1 (T1D)

Beyond the preview

Go deeper on jRCT2080223613.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2080223613.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call